Literature DB >> 23504695

Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.

Rimas V Lukas1, Martin Kelly Nicholas, Victoria Villaflor, Philip C Hoffman, Ravi Salgia.   

Abstract

BACKGROUND: Patients with lung cancer who develop brain metastases have a poor prognosis. Those patients with progressive brain metastases tend to have a dismal prognosis. Currently, there is no standard of care for the treatment of these patients.
METHODS: In this manuscript, we present a retrospective evaluation of 10 patients treated at our institution with a combination of temozolomide and/or erlotinib after disease progression in the central nervous system following radiation therapy.
RESULTS: Median overall survival was 28 weeks. Median time to progression in the central nervous system was 14 weeks. Median time to progression systemically was 7.5 weeks. Some patients demonstrated prolonged stability of disease.
CONCLUSIONS: A palliative regimen of temozolomide and/or erlotinib could be considered in progressive central nervous system metastases from lung cancer.

Entities:  

Keywords:  Brain metastases; Epidermal growth factor receptor; Erlotinib; Lung cancer; Temozolomide

Year:  2012        PMID： 23504695      PMCID： PMC3596833          DOI： 10.4021/jnr85w

Source DB:  PubMed          Journal:  J Neurol Res        ISSN： 1923-2845


  42 in total

Review 1.  Brain metastases.

Authors:  Mark E Shaffrey; Melike Mut; Anthony L Asher; Stuart H Burri; Ali Chahlavi; Susan M Chang; Elana Farace; John B Fiveash; Frederick F Lang; M Beatriz S Lopes; James M Markert; David Schiff; Vitaly Siomin; Stephen B Tatter; Michael A Vogelbaum
Journal:  Curr Probl Surg       Date:  2004-08       Impact factor: 1.909

2.  Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.

Authors:  Nirav Dhruva; Mark A Socinski
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

3.  Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

Authors:  Britta Weber; Michael Winterdahl; Ashfaque Memon; Boe S Sorensen; Susanne Keiding; Leif Sorensen; Ebba Nexo; Peter Meldgaard
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

4.  Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.

Authors:  Benjamin L Ebert; Ewa Niemierko; Kitt Shaffer; Ravi Salgia
Journal:  Oncologist       Date:  2003

5.  Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.

Authors:  Shenglin Ma; Yaping Xu; Qinghua Deng; Xinmin Yu
Journal:  Lung Cancer       Date:  2008-12-16       Impact factor: 5.705

Review 6.  Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.

Authors:  Yoshinobu Namba; Takashi Kijima; Soichiro Yokota; Manabu Niinaka; Satolo Kawamura; Takeo Iwasaki; Yoshito Takeda; Hiromi Kimura; Tatsuya Okada; Toshihiko Yamaguchi; Masaru Nakagawa; Yoshimoto Okumura; Hajime Maeda; Masami Ito
Journal:  Clin Lung Cancer       Date:  2004-09       Impact factor: 4.785

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Value of whole brain re-irradiation for brain metastases--single centre experience.

Authors:  E Sadikov; A Bezjak; Q-L Yi; W Wells; L Dawson; B-A Millar; N Laperriere
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-07-26       Impact factor: 4.126

9.  O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.

Authors:  Pei-Fang Wu; Kuan-Ting Kuo; Lu-Ting Kuo; Yi-Ting Lin; Wei-Chung Lee; Yen-Shen Lu; Chih-Hsin Yang; Ruey-Meei Wu; Yong-Kwang Tu; Jui-Chang Tasi; Ham-Min Tseng; Sheng-Hong Tseng; Ann-Lii Cheng; Ching-Hung Lin
Journal:  Lung Cancer       Date:  2009-09-08       Impact factor: 5.705

Review 10.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130
View more
  3 in total

Review 1.  Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Authors:  Rimas V Lukas; Maciej S Lesniak; Ravi Salgia
Journal:  CNS Oncol       Date:  2014-01

Review 2.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

3.  Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer.

Authors:  Heng Lin; Shuimei Luo; Lina Li; Sijing Zhou; Ruifen Shen; Haitao Yang; Yupeng Wu; Xianhe Xie
Journal:  Mol Clin Oncol       Date:  2017-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.